Kura Oncology (KURA) Competitors $8.25 -0.19 (-2.25%) Closing price 04:00 PM EasternExtended Trading$8.35 +0.10 (+1.20%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KURA vs. IMVT, XENE, VKTX, OGN, KNSA, NAMS, BHC, GMTX, CGON, and MLYSShould you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Immunovant (IMVT), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), CG Oncology (CGON), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Kura Oncology vs. Its Competitors Immunovant Xenon Pharmaceuticals Viking Therapeutics Organon & Co. Kiniksa Pharmaceuticals International NewAmsterdam Pharma Bausch Health Cos Gemini Therapeutics CG Oncology Mineralys Therapeutics Kura Oncology (NASDAQ:KURA) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership. Do analysts recommend KURA or IMVT? Kura Oncology currently has a consensus target price of $24.10, suggesting a potential upside of 192.12%. Immunovant has a consensus target price of $33.60, suggesting a potential upside of 127.33%. Given Kura Oncology's higher probable upside, equities analysts clearly believe Kura Oncology is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.80Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do institutionals & insiders hold more shares of KURA or IMVT? 47.1% of Immunovant shares are owned by institutional investors. 6.4% of Kura Oncology shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, KURA or IMVT? Kura Oncology has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Does the media refer more to KURA or IMVT? In the previous week, Kura Oncology had 10 more articles in the media than Immunovant. MarketBeat recorded 10 mentions for Kura Oncology and 0 mentions for Immunovant. Immunovant's average media sentiment score of 1.68 beat Kura Oncology's score of 0.57 indicating that Immunovant is being referred to more favorably in the news media. Company Overall Sentiment Kura Oncology Positive Immunovant Very Positive Is KURA or IMVT more profitable? Kura Oncology's return on equity of -52.32% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -52.32% -29.59% Immunovant N/A -80.99%-72.23% Which has preferable valuation & earnings, KURA or IMVT? Kura Oncology has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$83.28M8.60-$173.98M-$2.26-3.65ImmunovantN/AN/A-$413.84M-$2.85-5.19 SummaryKura Oncology beats Immunovant on 10 of the 14 factors compared between the two stocks. Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KURA vs. The Competition Export to ExcelMetricKura OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$716.08M$3.13B$5.76B$10.42BDividend YieldN/A2.37%5.74%4.63%P/E Ratio-3.6520.6576.5526.74Price / Sales8.60386.12495.39162.18Price / CashN/A45.3237.1760.63Price / Book1.559.6613.726.40Net Income-$173.98M-$53.02M$3.29B$271.71M7 Day Performance0.73%1.09%1.03%2.85%1 Month Performance14.74%7.93%6.32%9.64%1 Year Performance-60.86%10.48%81.16%31.62% Kura Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KURAKura Oncology4.0435 of 5 stars$8.25-2.3%$24.10+192.1%-58.3%$716.08M$83.28M-3.65130Gap UpIMVTImmunovant2.4184 of 5 stars$15.53-3.9%$33.60+116.4%-46.7%$2.82BN/A-5.45120Positive NewsXENEXenon Pharmaceuticals2.4065 of 5 stars$35.99-0.6%$53.30+48.1%-5.8%$2.79B$7.50M-10.14210Positive NewsOptions VolumeVKTXViking Therapeutics4.2767 of 5 stars$24.08-2.9%$87.50+263.4%-59.6%$2.79BN/A-15.7420Positive NewsOGNOrganon & Co.4.5327 of 5 stars$10.39-2.5%$17.33+66.9%-45.6%$2.77B$6.40B3.864,000Positive NewsKNSAKiniksa Pharmaceuticals International2.7379 of 5 stars$36.56-1.5%$41.17+12.6%+42.1%$2.75B$423.24M914.23220Insider TradeShort Interest ↑NAMSNewAmsterdam Pharma3.2911 of 5 stars$24.12-0.3%$41.55+72.2%+67.6%$2.72B$45.56M-14.894Positive NewsBHCBausch Health Cos4.6835 of 5 stars$7.17-1.2%$9.00+25.5%-13.6%$2.69B$9.63B27.5820,700GMTXGemini TherapeuticsN/A$59.82-0.8%N/A+28.1%$2.59BN/A-59.8230News CoverageCGONCG Oncology2.6361 of 5 stars$34.60+3.8%$53.91+55.8%+4.7%$2.54B$1.14M-19.5561Analyst ForecastAnalyst RevisionGap UpMLYSMineralys Therapeutics2.5489 of 5 stars$36.21-2.4%$43.50+20.1%+241.1%$2.46BN/A-10.1728Insider Trade Related Companies and Tools Related Companies IMVT Alternatives XENE Alternatives VKTX Alternatives OGN Alternatives KNSA Alternatives NAMS Alternatives BHC Alternatives GMTX Alternatives CGON Alternatives MLYS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KURA) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
